Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Details) - Schedule of financial information represents the operating results of the reportable segments

v3.22.0.1
Segment Reporting (Details) - Schedule of financial information represents the operating results of the reportable segments - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2022
Jan. 31, 2021
Clinical Services [Member]        
Segment Reporting Information [Line Items]        
Revenues $ 23,674 $ 23,988 $ 43,415 $ 45,211
Operating costs and expenses:        
Cost of revenues 12,586 11,708 23,789 24,703
Research and development 89 160 96 281
Selling, general and administrative 6,811 6,425 12,812 12,523
Legal fee expense 148 71 205 96
Total operating costs and expenses 19,634 18,364 36,902 37,603
Operating income (loss) 4,040 5,624 6,513 7,608
Other income (expense):        
Interest, net (3) (4) (5) (10)
Other 5 14 54 29
Foreign exchange loss    
Net income (loss) 4,042 5,634 6,562 7,627
Depreciation and amortization included above 438 381 856 790
Share-based compensation included in above:        
Selling, general and administrative 16 10 36 19
Cost of revenues 12 14 16 27
Total 28 24 52 46
Capital expenditures 283 341 593 881
Products [Member]        
Segment Reporting Information [Line Items]        
Revenues 10,372 7,478 17,150 14,910
Operating costs and expenses:        
Cost of revenues 5,252 3,937 9,322 7,700
Research and development 711 633 1,443 1,225
Selling, general and administrative 3,039 2,593 6,134 5,038
Legal fee expense 1 13 6
Total operating costs and expenses 9,002 7,164 16,912 13,969
Operating income (loss) 1,370 314 238 941
Other income (expense):        
Interest, net 9 8 18 18
Other 3 2 5 4
Foreign exchange loss (450) 625 (831) 461
Net income (loss) 932 949 (570) 1,424
Depreciation and amortization included above 190 188 402 373
Share-based compensation included in above:        
Selling, general and administrative 1 16 1 32
Cost of revenues  
Total 1 16 1 32
Capital expenditures 730 154 1,216 198
Therapeutics [Member]        
Segment Reporting Information [Line Items]        
Revenues  
Operating costs and expenses:        
Cost of revenues  
Research and development 20 13 25 46
Selling, general and administrative 16 33
Legal fee expense  
Total operating costs and expenses 20 29 25 79
Operating income (loss) (20) (29) (25) (79)
Other income (expense):        
Interest, net  
Other  
Foreign exchange loss    
Net income (loss) (20) (29) (25) (79)
Depreciation and amortization included above  
Share-based compensation included in above:        
Selling, general and administrative  
Cost of revenues  
Total      
Capital expenditures      
Other [Member]        
Segment Reporting Information [Line Items]        
Revenues  
Operating costs and expenses:        
Cost of revenues  
Research and development  
Selling, general and administrative 4,616 1,979 6,572 3,433
Legal fee expense 2,697 2,220 3,909 2,830
Total operating costs and expenses 7,313 4,199 10,481 6,263
Operating income (loss) (7,313) (4,199) (10,481) (6,263)
Other income (expense):        
Interest, net 62 (53) 94 (108)
Other (358) (554)  
Foreign exchange loss    
Net income (loss) (7,609) (4,252) (10,941) (6,371)
Depreciation and amortization included above 77 66 148 132
Share-based compensation included in above:        
Selling, general and administrative 650 136 842 265
Cost of revenues  
Total 650 136 842 265
Capital expenditures 201 11 438 44
Consolidated [Member]        
Segment Reporting Information [Line Items]        
Revenues 34,046 31,466 60,565 60,121
Operating costs and expenses:        
Cost of revenues 17,838 15,645 33,111 32,403
Research and development 820 806 1,564 1,552
Selling, general and administrative 14,466 11,013 25,518 21,027
Legal fee expense 2,845 2,292 4,127 2,932
Total operating costs and expenses 35,969 29,756 64,320 57,914
Operating income (loss) (1,923) 1,710 (3,755) 2,207
Other income (expense):        
Interest, net 68 (49) 107 (100)
Other (350) 16 (495) 33
Foreign exchange loss (450) 625 (831) 461
Net income (loss) (2,655) 2,302 (4,974) 2,601
Depreciation and amortization included above 705 635 1,406 1,295
Share-based compensation included in above:        
Selling, general and administrative 667 162 879 316
Cost of revenues 12 14 16 27
Total 679 176 895 343
Capital expenditures $ 1,214 $ 506 $ 2,247 $ 1,123